A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

Moderate to Severe Chronic Pain Clinical Trial

Official title:

A Phase 1 Double-Blind, Double-Dummy, Parallel-Group, Randomized, Positive Control Study Using fMRI to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03802227
• Other study ID #: 18-181-26
• Status: Terminated
• Phase: Phase 1
• Start date: October 22, 2018
• Est. completion date: January 3, 2020

Study information

• Verified date: July 2021
• Source: Nektar Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.

Description:

This study is a single-center study in which approximately 24 subjects will be randomized to one of two treatment groups. Subjects will enter a screening period between Day -28 and Day -2. Upon meeting all criteria for enrollment, on Day -1 subjects will enter the clinical research study unit (CRSU) for an overnight confinement. On Day 1, subjects will undergo a baseline MRI and will then be randomized to NKTR-181 or oxycodone immediate release (IR). Once randomized, subjects will receive a single dose of study drug (NKTR-181 or oxycodone IR) and matched alternate-treatment placebo. Subjects will undergo a series of three fMRIs (functional magnetic resonance imaging) post dose (at hours 1, 2, and 4). At post-dose hours 0.5, 1, 2, 3, 4, 5, 6, and 8, pupillometry will be performed and PK blood samples will be drawn. Following a 14- to 17-day safety follow-up period, subjects will return to the research facility clinic for the End of Study (EOS) visit (Day 16-19).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: January 3, 2020
• Est. primary completion date: December 17, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Key Inclusion Criteria:

• Healthy male and female recreational opioid users, 18-65 years of age inclusive.

• Body Mass Index (BMI) between 19.0 to 45.0kg/m2

• Have at least one urine drug screen positive for opioids during Screening to confirm recreational opioid use. Subjects testing positive for methadone or buprenorphine prescribed for treatment will be excluded.

• Subjects must agree to practice adequate contraception as outlined in the protocol.

Key Exclusion Criteria:

• Any metal fragments or other bodily metal that would pose a risk to subjects during MRI scanning as determined by the MRI technologist and/or MRI physicist

• Any clinically significant disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous, or gastrointestinal systems or other conditions that may interfere with the absorption, distribution, metabolism, or excretion of the study drug or would place the subject at increased risk

• History of clinically significant acute asthma or other obstructive airway disease requiring daily controller medication or any condition that may increase the risk for respiratory depression

• Current neurologic conditions such as convulsive disorders, or history of severe head injury.

• Any current DSM-5 axis I psychiatric disorder or neurological disorder requiring ongoing treatment

• Current substance use disorder (moderate to severe), other than Opioid, Nicotine, THC (tetrahydrocannabinol), cocaine, or caffeine as defined by DSM-5

• Physical dependence of opioids

• History of claustrophobia or any other psychiatric disorder that would preclude subject tolerance of MRI procedures.

• Current use of any medication that could affect central nervous system blood flow (e.g. certain cardiovascular medications, triptan migraine medications)

• Clinical Opiate Withdrawal Scale (COWS) score of greater than 5 during screening or prior to first scan.

• Positive urine drug screen for buprenorphine or methadone immediately prior to the first scan.

Related Conditions & MeSH terms

• Chronic Pain
• Moderate to Severe Chronic Pain

Intervention

Drug:
• NKTR-181
A combination of NKTR-181 and oxycodone IR placebo
• Oxycodone IR
A combination of oxycodone IR and NKTR-181 placebo

Locations

Country	Name	City	State
United States	Investigator Site - Richmond	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Nektar Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain Activity Measured Via fMRI	The primary objective of the study was to evaluate the effects of NKTR-181 on brain activity. Functional MRI assessments in subjects administered opioids such as morphine, buprenorphine, and nalbuphine have shown drug-induced signaling changes in reward structures such as the nucleus accumbens, orbitofrontal cortex, and hippocampus, as well as changes in the functional connectivity of reward circuitry (Becerra, 2006; Gear, 2013; Upadhyay, 2012).	8 hour period following dose of NKTR-181
Secondary	Change in Pupil Diameter Via Pupillometry	Analysis of change in pupil diameter after administration of NKTR-181 or Oxycodone IR.	24 hour period following dose administration Day 1 to 2
Secondary	Plasma Drug Concentration	Plasma drug concentration for NKTR-181 and Oxycodone IR over 24 hours.	24 hour period following dose administration Day 1 to 2
Secondary	Time to Maximum Concentration (Tmax)	The amount of time needed for maximum drug concentration to be reached.	24 hour period following dose administration Day 1 to 2
Secondary	Treatment-Emergent Adverse Events (TEAEs)	Number of patients who experienced any type of adverse event as a result of one of the treatments.	19 days